OBJECTIVE: To probe into the effect of pentoxifylline on the improvement of cognition impairment in patients with non-demented vascular cognitive impairment. METHODS: Totally 55 patients with non-demented vascular cognitive impairment admitted into the Eighth People’s Hospital of Hebei Province from Jun. 2019 to Aug. 2020 were selected and divided into control group（ 27 cases） and observation group（ 28 cases） via random number table. The control group was given conventional therapy

while the observation group was treated with Pentoxifylline sustainedrelease tablets based on the control group. The regional cerebral blood flow

neurological function deficit score（ NFDS）

activity of daily living（ ADL） score and cognitive function scores[mini mental status examination（ MMSE）

Montreal Cognitive Assessment（ Mo CA） ]of the two groups were observed

and drug safety evaluation was performed. RESULTS:Compared with the control group

the observation group had significantly higher blood flow in all cerebral regions

significantly lower NFDS score and significantly higher ADL

MMSE and Mo CA scores at 1

3 and 6 months of treatment

all these differences were statistically significant（ P

<

0. 05）. The incidences of adverse drug reactions of observation group and control group were respectively 3. 57%（ 1/28） and 7. 41%（ 2/27）

the difference was not statistically significant（ χ

2

= 0. 001

P = 0. 974）. CONCLUSIONS: Pentoxifylline can effectively improve the clinical symptoms of patients with non-demented vascular cognitive impairment

improve the blood flow volume of cerebral vessel

reduce NFDS scores

promote ADL

MMSE and Mo CA scores

with significant clinical efficacy and high safety.